<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171029037068N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-23</date_registration>
      <primary_sponsor>Ferdowsi University of Mashhad</primary_sponsor>
      <public_title>Transdiagnostic therapy based on the research domain criteria framework for non-suicidal self-injury</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of transdiagnostic therapy based on the research domain criteria framework compared with treatment as usual and transcranial direct current stimulation for youth non-suicidal self-injury: A randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70159</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The simple randomization method was performed with the help of SAS software. In this way, each subject is registered in the software and a code is defined for each person. Then, by means of the software, they are randomly divided into three intervention groups, Blinding description: Participants assumed that all participants would receive the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Nonsuicidal self-injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: TTB-RDoC is a group intervention program for youth with NSSI (18–30-year-olds). It comprises 16 sessions (twice a week) of 45 min. This program consists of four modules. Module 1: Emotion Regulation, Module 2: Cognitive Training, Module 3: Behavioral Activation and Module 4: Interpersonal Skills. Each module is held in 4 sessions. Intervention 2: Intervention group 2: The tDCS will deliver using two 5×7 cm electrodes covered in saline-soaked sponges. Electrodes were placed with a bipolar-balanced montage with anode on the right DLPFC (F4) and cathode on the left DLPFC (F3) according to EEG 10-20 system. tDCS was administered in a daily session lasting 20 min for 5 working days/week for 4 consecutive weeks. Intervention 3: Control group: TAU protocol includes new techniques from 'third' wave CBT, Acceptance Commitment Therapy (ACT) and Dialectical Behavior Therapy (DBT). The manual is evidence based and focuses on a flexible and formulation driven model to direct treatment in 15 sessions of 45 minutes and 2 sessions a week for young people. Cognitive-behavioral methodological techniques were performed in 5 sessions, including correction of cognitive errors, emotional regulation, and behavioral activation. Treatment techniques of commitment and acceptance in 5 sessions and included cognitive breakdown, self as background, conscious mind, values and acceptance and commitment.Dialectical behavioral therapy techniques in 5 sessions and included mindfulness, distress tolerance, interpersonal effectiveness and emotion control.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential data can be shared after de-identifying individuals

When:
The data will become available 3 months after the results are published

To whom:
There is no specific limitation and it will be accessible to all researchers in this field

Conditions:
Currently, there are no special conditions and restrictions

Where to obtain:
We will respond to applicants via email

How to obtain:
The aims and objectives of the research should be clearly explained.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Imanollah Bigdeli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 10, Kalantari Blvd, Azadi Sq, Mashhad.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188355827</zip>
        <telephone>+98 51 3880 5865</telephone>
        <email>ibigdeli@um.ac.ir</email>
        <affiliation>Ferdowsi University of Mashhad</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hossein Farrokhi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 10, Kalantari Blvd, Azadi Sq, Mashhad.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188355827</zip>
        <telephone>+98 51 3868 0489</telephone>
        <email>hossein.farrokhi110@gmail.com</email>
        <affiliation>Ferdowsi University of Mashhad</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primary DSM-5 diagnosis of non-suicidal self-injury (NSSI)
No usage of medication
Being at the age of 18-30 years old
Speaking Persian fluently
Ability to participate in all assessment and treatment sessions</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Need for immediate medical treatment or the need for concurrent therapeutic interventions that would interfere with the treatment program
Receiving a full course of pharmacotherapy or psychotherapy, within the past 5 years
Having psychiatric disorders and substance abuse (except tobacco users) within twelve months before screening
Current diagnosis of any mental disorder
A history of epilepsy
Significant head injury or other neurological conditions, or brain surgery
A history of adverse reaction to tDCS or having a sensitive scalp
Patient's opposition to collaboration at any time of research
Having serious thoughts about suicide</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: TTB-RDoC is a group intervention program for youth with NSSI (18–30-year-olds). It comprises 16 sessions (twice a week) of 45 min. This program consists of four modules. Module 1: Emotion Regulation, Module 2: Cognitive Training, Module 3: Behavioral Activation and Module 4: Interpersonal Skills. Each module is held in 4 sessions.</i_keyword>
      <i_keyword>Intervention group 2: The tDCS will deliver using two 5×7 cm electrodes covered in saline-soaked sponges. Electrodes were placed with a bipolar-balanced montage with anode on the right DLPFC (F4) and cathode on the left DLPFC (F3) according to EEG 10-20 system. tDCS was administered in a daily session lasting 20 min for 5 working days/week for 4 consecutive weeks</i_keyword>
      <i_keyword>Control group: TAU protocol includes new techniques from 'third' wave CBT, Acceptance Commitment Therapy (ACT) and Dialectical Behavior Therapy (DBT). The manual is evidence based and focuses on a flexible and formulation driven model to direct treatment in 15 sessions of 45 minutes and 2 sessions a week for young people. Cognitive-behavioral methodological techniques were performed in 5 sessions, including correction of cognitive errors, emotional regulation, and behavioral activation. Treatment techniques of commitment and acceptance in 5 sessions and included cognitive breakdown, self as background, conscious mind, values and acceptance and commitment.Dialectical behavioral therapy techniques in 5 sessions and included mindfulness, distress tolerance, interpersonal effectiveness and emotion control.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nonsuicidal self-injury. Timepoint: At baseline (pre-treatment), at 8th weeks (post-treatment), and after a 12-month post-treatment followup period. Method of measurement: Inventory of statements about self-injury (ISAS), Structured clinical interview for DSM‐5 disorders‐clinician version.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ferdowsi University of Mashhad</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-14</approval_date>
        <contact_name>Research Ethics Committee of Ferdowsi University of Mashhad</contact_name>
        <contact_address>No. 10, Kalantari Blvd, Azadi Sq, Mashhad. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
